Annual report pursuant to Section 13 and 15(d)

Segment Information (Schedule of Segment Information) (Details)

v3.21.1
Segment Information (Schedule of Segment Information) (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]      
Net Revenue $ 45,599,000 $ 36,629,000  
Direct cost of goods (14,594,000) (10,532,000)  
Sales and marketing costs (17,384,000) (17,120,000)  
Research and development (64,109,000) (81,326,000)  
General and administrative (43,782,000) (38,470,000)  
Other income (expense) (8,579,000) 9,159,000  
Income tax expense (136,000) 0  
Net loss (102,985,000) (101,660,000)  
Intangible asset, net 14,629,000 7,377,000 $ 1,417,000
Tangible assets 314,205,000 219,045,000  
Total assets 328,834,000 226,422,000  
Dermatology Products Sales [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 44,531,000 34,921,000  
Direct cost of goods (14,594,000) (10,532,000)  
Sales and marketing costs (17,384,000) (17,120,000)  
Research and development 0 0  
General and administrative (4,716,000) (2,556,000)  
Other income (expense) (697,000) 0  
Income tax expense (96,000)    
Net loss 7,044,000 4,713,000  
Intangible asset, net 14,629,000 7,377,000  
Tangible assets 30,843,000 19,946,000  
Total assets 45,472,000 27,323,000  
Pharmaceutical and Biotechnology Product Development [Member]      
Segment Reporting Information [Line Items]      
Net Revenue 1,068,000 1,708,000  
Direct cost of goods 0 0  
Sales and marketing costs 0 0  
Research and development (64,109,000) (81,326,000)  
General and administrative (39,066,000) (35,914,000)  
Other income (expense) (7,882,000) 9,159,000  
Income tax expense (40,000)    
Net loss (110,029,000) (106,373,000)  
Intangible asset, net 0 0  
Tangible assets 283,362,000 199,099,000  
Total assets $ 283,362,000 $ 199,099,000